AU2016289755C1 - Tau-binding antibodies - Google Patents

Tau-binding antibodies Download PDF

Info

Publication number
AU2016289755C1
AU2016289755C1 AU2016289755A AU2016289755A AU2016289755C1 AU 2016289755 C1 AU2016289755 C1 AU 2016289755C1 AU 2016289755 A AU2016289755 A AU 2016289755A AU 2016289755 A AU2016289755 A AU 2016289755A AU 2016289755 C1 AU2016289755 C1 AU 2016289755C1
Authority
AU
Australia
Prior art keywords
ser
tau
gly
thr
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016289755A
Other languages
English (en)
Other versions
AU2016289755B2 (en
AU2016289755A1 (en
Inventor
Terence Seward Baker
Jean-Philippe COURADE
Patrick Downey
Robert Anthony Griffin
David Edward Ormonde KNIGHT
Georges MAIRET-COELLO
David James MCMILLAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53524640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2016289755(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of AU2016289755A1 publication Critical patent/AU2016289755A1/en
Assigned to UCB Biopharma SRL reassignment UCB Biopharma SRL Amend patent request/document other than specification (104) Assignors: UCB BIOPHARMA SPRL
Publication of AU2016289755B2 publication Critical patent/AU2016289755B2/en
Application granted granted Critical
Publication of AU2016289755C1 publication Critical patent/AU2016289755C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
AU2016289755A 2015-07-06 2016-07-05 Tau-binding antibodies Active AU2016289755C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15175522 2015-07-06
EP15175522.0 2015-07-06
PCT/EP2016/065813 WO2017005734A1 (en) 2015-07-06 2016-07-05 Tau-binding antibodies

Publications (3)

Publication Number Publication Date
AU2016289755A1 AU2016289755A1 (en) 2018-01-04
AU2016289755B2 AU2016289755B2 (en) 2020-12-03
AU2016289755C1 true AU2016289755C1 (en) 2021-08-19

Family

ID=53524640

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016289755A Active AU2016289755C1 (en) 2015-07-06 2016-07-05 Tau-binding antibodies

Country Status (31)

Country Link
US (4) US10287343B2 (enExample)
EP (2) EP4729538A3 (enExample)
JP (3) JP6630426B2 (enExample)
KR (2) KR20250027278A (enExample)
CN (1) CN107849104B (enExample)
AR (1) AR105267A1 (enExample)
AU (1) AU2016289755C1 (enExample)
CA (1) CA2991451A1 (enExample)
CL (1) CL2018000043A1 (enExample)
CO (1) CO2017012971A2 (enExample)
EA (1) EA037092B1 (enExample)
EC (1) ECSP18000887A (enExample)
ES (1) ES3060419T3 (enExample)
HR (1) HRP20260348T1 (enExample)
IL (1) IL256685B (enExample)
MA (2) MA42377B1 (enExample)
MD (1) MD3319983T2 (enExample)
MX (1) MX2017015817A (enExample)
MY (1) MY193677A (enExample)
PE (1) PE20180481A1 (enExample)
PH (1) PH12017502207B1 (enExample)
PL (1) PL3319983T3 (enExample)
RS (1) RS67937B1 (enExample)
SG (1) SG10202010735PA (enExample)
SM (1) SMT202600068T1 (enExample)
TN (1) TN2017000539A1 (enExample)
TW (1) TWI745295B (enExample)
UA (1) UA124616C2 (enExample)
UY (1) UY36773A (enExample)
WO (1) WO2017005734A1 (enExample)
ZA (1) ZA201800027B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ775762A (en) 2015-06-05 2025-02-28 Genentech Inc Anti-tau antibodies and methods of use
SG10202010735PA (en) 2015-07-06 2020-11-27 UCB Biopharma SRL Tau-binding antibodies
CA2991264C (en) 2015-07-06 2023-10-10 Ucb Biopharma Sprl Tau-binding antibodies
EP3551655A2 (en) 2016-12-07 2019-10-16 Genentech, Inc. Anti-tau antibodies and methods of their use
EP3551220B1 (en) 2016-12-07 2025-01-29 Genentech, Inc. Anti-tau antibodies and methods of use
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CA3053379A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
JP6851549B2 (ja) 2017-10-16 2021-03-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗タウ抗体及びその使用
WO2020120644A1 (en) * 2018-12-13 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) New anti tau svqivykpv epitope single domain antibody
US20220299527A1 (en) * 2019-08-13 2022-09-22 Washington University Methods to detect mtbr tau isoforms and use thereof
CA3167317C (en) 2020-02-12 2025-05-27 Eli Lilly And Company CRYSTALLIZATION OF ANTIBODIES OR ANTIGEN-BINDING FRAGMENTS
CN116723856A (zh) 2020-06-25 2023-09-08 默沙东有限责任公司 靶向丝氨酸413处磷酸化的tau的高亲和力抗体
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
JP2025535203A (ja) 2022-09-15 2025-10-23 ボイジャー セラピューティクス インコーポレイテッド タウ結合化合物
CR20250208A (es) * 2022-11-14 2025-08-04 Washington University St Louis Métodos para detectar mtbr-tau en lcr y usos de los mismos
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025171285A1 (en) * 2024-02-09 2025-08-14 University Of Notre Dame Du Lac Tau proteomimetics
WO2025196217A1 (en) 2024-03-21 2025-09-25 UCB Biopharma SRL Treatment of tauopathies with tau-binding antibodies
WO2026057816A1 (en) 2024-09-13 2026-03-19 UCB Biopharma SRL Treatment of tauopathies with tau-binding antibodies
WO2026093448A1 (en) * 2024-10-30 2026-05-07 Universiteit Utrecht Holding B.V. Single-domain antibodies targeting the heparin-binding egf-like growth factor
WO2026102093A1 (en) 2024-11-07 2026-05-15 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013096380A2 (en) * 2011-12-20 2013-06-27 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
WO2014028777A2 (en) * 2012-08-16 2014-02-20 Ipierian, Inc. Methods of treating a tauopathy

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6566329B1 (en) 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
PT1644412E (pt) 2003-07-01 2015-12-23 Ucb Biopharma Sprl Fragmentos de anticorpos fab modificados
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
CN1721437A (zh) * 2004-07-13 2006-01-18 中南大学 一种与Tau蛋白相关的多肽抗原及抗体
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
EP2535350B1 (en) 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
CN101307108B (zh) * 2008-06-25 2012-04-04 南京川博生物技术有限公司 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途
US10407513B2 (en) 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
WO2010043047A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
CA2745527A1 (en) 2008-12-05 2010-06-10 Angiochem Inc. Leptin and leptin analog conjugates and uses thereof
WO2010063122A1 (en) 2008-12-05 2010-06-10 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
WO2011041897A1 (en) 2009-10-06 2011-04-14 Angiochem Inc. Compositions and methods for the transport of therapeutic agents
WO2012045882A2 (en) 2010-10-07 2012-04-12 Ac Immune S.A. Pharmaceutical composition
LT2627672T (lt) * 2010-10-11 2018-12-10 Biogen International Neuroscience Gmbh Žmogaus antikūnai prieš tau baltymą
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
EP3275461A1 (en) 2011-09-19 2018-01-31 Axon Neuroscience SE Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field
CA2853100A1 (en) * 2011-10-24 2013-05-02 Intellect Neurosciences, Inc. Compositions and methods for treatment of proteinopathies
JP6411214B2 (ja) 2011-11-11 2018-10-24 ユーシービー バイオファルマ エスピーアールエル アルブミン結合抗体及びその結合断片
EP2870176A4 (en) 2012-07-03 2016-09-28 Univ Washington ANTIBODIES DIRECTED AGAINST TAU
JP6284548B2 (ja) 2012-12-21 2018-02-28 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． ヒト抗タウ抗体
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
CA2991264C (en) 2015-07-06 2023-10-10 Ucb Biopharma Sprl Tau-binding antibodies
SG10202010735PA (en) 2015-07-06 2020-11-27 UCB Biopharma SRL Tau-binding antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013096380A2 (en) * 2011-12-20 2013-06-27 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
WO2014028777A2 (en) * 2012-08-16 2014-02-20 Ipierian, Inc. Methods of treating a tauopathy

Also Published As

Publication number Publication date
TWI745295B (zh) 2021-11-11
AU2016289755B2 (en) 2020-12-03
ZA201800027B (en) 2019-06-26
MY193677A (en) 2022-10-25
WO2017005734A1 (en) 2017-01-12
JP2022141689A (ja) 2022-09-29
JP2018524001A (ja) 2018-08-30
RS67937B1 (sr) 2026-04-30
EA201890172A1 (ru) 2018-10-31
PL3319983T3 (pl) 2026-06-01
SMT202600068T1 (it) 2026-03-09
PH12017502207A1 (en) 2018-06-11
ES3060419T3 (en) 2026-03-26
PE20180481A1 (es) 2018-03-07
KR102770650B1 (ko) 2025-02-19
US20180201666A1 (en) 2018-07-19
US10287343B2 (en) 2019-05-14
AU2016289755A1 (en) 2018-01-04
TW201713689A (zh) 2017-04-16
US11732034B2 (en) 2023-08-22
NZ738058A (en) 2021-07-30
KR20180025962A (ko) 2018-03-09
TN2017000539A1 (en) 2019-04-12
JP7100008B2 (ja) 2022-07-12
CO2017012971A2 (es) 2018-03-09
JP6630426B2 (ja) 2020-01-15
MA41670A1 (fr) 2018-05-31
UA124616C2 (uk) 2021-10-20
MD3319983T2 (ro) 2026-03-31
EP3319983A1 (en) 2018-05-16
MX2017015817A (es) 2018-04-10
CN107849104B (zh) 2021-08-27
SG10202010735PA (en) 2020-11-27
HK1246804A1 (zh) 2018-09-14
US20230416350A1 (en) 2023-12-28
IL256685A (en) 2018-03-29
AR105267A1 (es) 2017-09-20
UY36773A (es) 2017-01-31
JP7413448B2 (ja) 2024-01-15
EP3319983B1 (en) 2026-01-28
HRP20260348T1 (hr) 2026-04-24
CA2991451A1 (en) 2017-01-12
EP3319983C0 (en) 2026-01-28
EA037092B1 (ru) 2021-02-04
US10889640B2 (en) 2021-01-12
US20210115121A1 (en) 2021-04-22
BR112017028102A2 (en) 2018-09-04
KR20250027278A (ko) 2025-02-25
CN107849104A (zh) 2018-03-27
ECSP18000887A (es) 2018-03-31
CL2018000043A1 (es) 2018-05-18
EP4729538A2 (en) 2026-04-22
US20190284267A1 (en) 2019-09-19
JP2020055849A (ja) 2020-04-09
PH12017502207B1 (en) 2022-08-10
MA42377A (fr) 2018-05-16
EP4729538A3 (en) 2026-06-24
MA42377B1 (fr) 2026-04-30
IL256685B (en) 2022-02-01

Similar Documents

Publication Publication Date Title
AU2016289755B2 (en) Tau-binding antibodies
TWI748954B (zh) Ｔａｕ結合抗體
AU2012347972B2 (en) PDGF receptor beta binding polypeptides
TWI545132B (zh) 人類化抗－ＴＡＵ（ｐＳ４２２）抗體及使用方法
KR100442019B1 (ko) 사구체신염 및 다른 염증 질환의 치료방법 및 치료용 조성물
ES2728278T3 (es) Composiciones que comprenden anticuerpos dirigidos al factor P y C5
KR102178323B1 (ko) 항 c-Met/항 Ang2 이중 특이 항체
KR102150616B1 (ko) c-Met 표적 화합물-생체활성 물질 접합체 및 그 용도
KR102390359B1 (ko) 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
KR101981943B1 (ko) 항-cd43 항체 및 이의 암 치료 용도
KR102277813B1 (ko) 항 c-Met 항체의 항-이디오타입 항체
TW202014209A (zh) 用於消融造血幹細胞之抗體藥物軛合物
KR101985299B1 (ko) 항-c-Met/항-Nrp1 이중 특이 항체
HK1246804B (en) Tau-binding antibodies
KR20150088433A (ko) c-Met 저해제의 효능 예측을 위한 바이오마커 TFF1
CN105925610B (zh) 昆虫杆状病毒表达载体、构建方法及其应用
KR20150133576A (ko) 화학적 개질된 표적화 단백질 및 그의 이용
KR102291465B1 (ko) c-Met 저해제의 효능 예측을 위한 바이오마커 TFF1
KR102177785B1 (ko) c-Met 항체의 효능 검사용 마커 및 이를 이용하는 c-Met 항체의 효능 검사 방법
KR20160024639A (ko) c-Met 표적 치료제의 저항성 또는 효능 예측을 위한 바이오마커 PDGF
HK1245810B (en) Tau-binding antibodies
HK1202882B (en) Pdgf receptor beta binding polypeptides

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: UCB BIOPHARMA SRL

Free format text: FORMER NAME(S): UCB BIOPHARMA SPRL

FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 13 APR 2021

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 13 APR 2021